Demetrix Inc., a biotechnology company that makes safe and effective cannabinoids, has commenced 15,000-liter demo-scale fermentation production of the rare cannabinoid cannabigerol (CBG).
The company's demo-scale production follows the successful completion of numerous pilot-scale fermentations and is a critical milestone towards the commercialization of rare cannabinoids for a range of safe, effective and legal health and wellness products, from pharmaceuticals to skincare.
Demetrix has created a fermentation technology platform that allows the company to produce high-purity rare cannabinoids faster, more sustainably and more affordably than traditional methods. The company has gone from initial technology development to demo scale production in just three years.
"Demetrix believes in the power of science to make the world a better place,” said Demetrix CEO Jeff Ubersax. “By bringing scientific rigor to the production and study of cannabinoids, we're pioneering a future of safe, effective and legal products that use these rare, incredibly promising compounds to improve the health and wellness of millions of people. Achieving demo scale production is a significant milestone that proves how fast and effective our team has been in solving some of the biggest challenges in producing cannabinoids with fermentation. We're well on our way to large scale commercialization."
Demetrix is a venture-backed company that has secured $61 million dollars to date. The company's team is made up of industry veterans with a long history of innovation and bringing fermentation products to market, with experts in R&D, production, regulation and commercialization.